The MClean Screening Instrument for Borderline Personality Disorder (MSI-BPD) and Zanarini Rating Scale for Borderline Personalty Disorder (Zan-Bpd) both assessment instruments were created by Mary C. Zanarini, EdD-Director, Laboratory for the Study of Adult Development , McLean Hospital, Belmont, Massachusetts, Associate Professor of Psychology, Harvard Medical School, Boston, Massachusetts.
Objective: The authors compared the efficacy and tolerability of low and mod-erate dosages of extended-release quetia-pine in adults with borderline personality disorder. Method: Ninety-five participants with DSM-IV borderline personality disorderwere randomly assigned to receive 150mg/day of quetiapine (the low-dosage group; N=33), 300 mg/day of quetiapine (the moderate-dosage group; N=33), or placebo (N=29). Total score over time on the clinician-rated Zanarini Rating Scale for Borderline Person-ality Disorder (“Zanarini scale”) was analyzed in a mixed-effects model accounting for in-
Mean visit-wise changes in Zanarini Rating Scale for Borderline Personality Disorder (ZAN–BPD) total scores (mixed-effects model repeated measures), and mean baseline to end-point change in ZAN–BPD total score, last observation carried forward (LOCF). a. Type III sum of squares (ANOVA): model = baseline, investigator, therapy; P=0.661. *P